A Phase II Trial of IPH2101 (Anti-KIR) in Smoldering Multiple Myeloma (SMM).
Phase of Trial: Phase II
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Lirilumab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 14 May 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 03 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 03 Jul 2012 Actual patient number is 9 according to ClinicalTrials.gov.